Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.31 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12601164 | 0.90 | ASGR1 (0.33) | ALDH1A1L3MBTL1PKM | |
| SCHEMBL10209192 | 0.84 | ALDH1A1 (0.40) | ALDH1A1L3MBTL1PKMKMT2ACA1 | |
| SCHEMBL12560770 | 0.82 | MAPK1 (0.40) | ALDH1A1L3MBTL1PKMKMT2ACA1 | |
| SCHEMBL7567193 | 0.80 | ALDH1A1 (0.36) | ALDH1A1L3MBTL1PKMKMT2ACA1 | |
| SCHEMBL7886992 | 0.80 | ALDH1A1 (0.36) | ALDH1A1L3MBTL1PKMKMT2ACA1 | |
| SCHEMBL7889397 | 0.80 | ALDH1A1 (0.36) | ALDH1A1L3MBTL1PKMKMT2ACA1 | |
| SCHEMBL12560736 | 0.79 | MAPK1 (0.40) | L3MBTL1KMT2A | |
| SCHEMBL12391259 | 0.79 | KMT2A (0.47) | ALDH1A1L3MBTL1PKMKMT2ACA1 | |
| SCHEMBL2503399 | 0.79 | KMT2A (0.47) | ALDH1A1L3MBTL1PKMKMT2ACA1 | |
| SCHEMBL16367194 | 0.79 | KMT2A (0.47) | ALDH1A1L3MBTL1PKMKMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399634-B2 | Reagents and methods for preparing LPS antagonist B1287 and stereoisomers thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20110152508-A1 | REAGENTS AND METHODS FOR PREPARING LPS ANTAGONIST B1287 AND STEREOISOMERS THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152508-A1 | REAGENTS AND METHODS FOR PREPARING LPS ANTAGONIST B1287 AND STEREOISOMERS THEREOF | LTB4R2, LTB4R, LITAF | ALDH1A1 3887/4885L3MBTL1 94/4885PKM 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.